These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18402432)

  • 1. Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.
    Gopi H; Umashankara M; Pirrone V; LaLonde J; Madani N; Tuzer F; Baxter S; Zentner I; Cocklin S; Jawanda N; Miller SR; Schön A; Klein JC; Freire E; Krebs FC; Smith AB; Sodroski J; Chaiken I
    J Med Chem; 2008 May; 51(9):2638-47. PubMed ID: 18402432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120.
    Gopi H; Cocklin S; Pirrone V; McFadden K; Tuzer F; Zentner I; Ajith S; Baxter S; Jawanda N; Krebs FC; Chaiken IM
    J Mol Recognit; 2009; 22(2):169-74. PubMed ID: 18498083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.
    Umashankara M; McFadden K; Zentner I; Schön A; Rajagopal S; Tuzer F; Kuriakose SA; Contarino M; Lalonde J; Freire E; Chaiken I
    ChemMedChem; 2010 Nov; 5(11):1871-9. PubMed ID: 20677318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.
    Rosemary Bastian A; Nangarlia A; Bailey LD; Holmes A; Kalyana Sundaram RV; Ang C; Moreira DR; Freedman K; Duffy C; Contarino M; Abrams C; Root M; Chaiken I
    J Biol Chem; 2015 Jan; 290(1):529-43. PubMed ID: 25371202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-natural peptide triazole antagonists of HIV-1 envelope gp120.
    Kamanna K; Aneja R; Duffy C; Kubinski P; Rodrigo Moreira D; Bailey LD; McFadden K; Schön A; Holmes A; Tuzer F; Contarino M; Freire E; Chaiken IM
    ChemMedChem; 2013 Feb; 8(2):322-8. PubMed ID: 23239505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.
    Emileh A; Tuzer F; Yeh H; Umashankara M; Moreira DR; Lalonde JM; Bewley CA; Abrams CF; Chaiken IM
    Biochemistry; 2013 Apr; 52(13):2245-61. PubMed ID: 23470147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter.
    Rashad AA; Kalyana Sundaram RV; Aneja R; Duffy C; Chaiken I
    J Med Chem; 2015 Sep; 58(18):7603-8. PubMed ID: 26331669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism.
    Tuzer F; Madani N; Kamanna K; Zentner I; LaLonde J; Holmes A; Upton E; Rajagopal S; McFadden K; Contarino M; Sodroski J; Chaiken I
    Proteins; 2013 Feb; 81(2):271-90. PubMed ID: 23011758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.
    Zhang S; Holmes AP; Dick A; Rashad AA; Enríquez Rodríguez L; Canziani GA; Root MJ; Chaiken IM
    Retrovirology; 2021 Oct; 18(1):31. PubMed ID: 34627310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
    Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM
    Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide triazole inactivators of HIV-1: how do they work and what is their potential?
    Chaiken I; Rashad AA
    Future Med Chem; 2015; 7(17):2305-10. PubMed ID: 26599515
    [No Abstract]   [Full Text] [Related]  

  • 13. Covalent conjugation of a peptide triazole to HIV-1 gp120 enables intramolecular binding site occupancy.
    Emileh A; Duffy C; Holmes AP; Rosemary Bastian A; Aneja R; Tuzer F; Rajagopal S; Li H; Abrams CF; Chaiken IM
    Biochemistry; 2014 Jun; 53(21):3403-14. PubMed ID: 24801282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.
    Courter JR; Madani N; Sodroski J; Schön A; Freire E; Kwong PD; Hendrickson WA; Chaiken IM; LaLonde JM; Smith AB
    Acc Chem Res; 2014 Apr; 47(4):1228-37. PubMed ID: 24502450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.
    Aneja R; Rashad AA; Li H; Kalyana Sundaram RV; Duffy C; Bailey LD; Chaiken I
    J Med Chem; 2015 May; 58(9):3843-58. PubMed ID: 25860784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.
    Bashir T; Patgaonkar M; Kumar SC; Pasi A; Reddy KV
    PLoS One; 2015; 10(4):e0124839. PubMed ID: 25915507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors.
    McFadden K; Fletcher P; Rossi F; Kantharaju ; Umashankara M; Pirrone V; Rajagopal S; Gopi H; Krebs FC; Martin-Garcia J; Shattock RJ; Chaiken I
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1073-80. PubMed ID: 22083481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.
    Neffe AT; Meyer B
    Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309
    [No Abstract]   [Full Text] [Related]  

  • 19. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.
    Gift SK; Zentner IJ; Schön A; McFadden K; Umashankara M; Rajagopal S; Contarino M; Duffy C; Courter JR; Zhang MY; Gershoni JM; Cocklin S; Dimitrov DS; Smith AB; Freire E; Chaiken IM
    Biochemistry; 2011 Apr; 50(14):2756-68. PubMed ID: 21351734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.
    Grupping K; Selhorst P; Michiels J; Vereecken K; Heyndrickx L; Kessler P; Vanham G; Martin L; Ariën KK
    Retrovirology; 2012 May; 9():36. PubMed ID: 22551420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.